Prodrugs for improving tumor targetability and efficiency

Advanced Drug Delivery Reviews

Volumn 63, Issue 8, 2011, Pages 659-670

  Mahato, Rubi ^a   Tai, Wanyi ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

ADEPT; Cancer therapy; GDEPT; Polymer; Prodrug; Targeted delivery; Transporter

Indexed keywords

ADEPT; CANCER THERAPY; GDEPT; PRODRUGS; TARGETED DELIVERY; TRANSPORTER;

CHEMICAL MODIFICATION; CHEMICAL STABILITY; CHEMOTHERAPY; DISEASES; ENZYMES; LIGANDS; POLYMERS;

TUMORS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMIDE; APTAMER; BESTATIN; CAMPTOTHECIN; CEPHALOSPORIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTER; ETOPOFOS; FLOXURIDINE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; IMINE; INOTUZUMAB OZOGAMICIN; IRINOTECAN; LORVOTUZUMAB MERTANSINE; MACROGOL; MITOMYCIN C; OXIME; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGAMOTECAN; PRODRUG; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DISTRIBUTION VOLUME; DISULFIDE BOND; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; ENDOCYTOSIS; ENZYME PRODRUG THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEMBRANE TRANSPORT; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; NEOPLASMS; POLYMERS; PRODRUGS;

EID: 79959972712     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.02.002     Document Type: Review

References (134)

1. Knox R.J., Connors T.A. Prodrugs in cancer chemotherapy. Pathol. Oncol. Res. 1997, 3(4):309-324.
2. Denny W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 2001, 36(7-8):577-595.
3. Rautio J., et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7(3):255-270.
4. Singh Y., Palombo M., Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15(18):1802-1826.
5. Muller C.E. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem. Biodivers. 2009, 6(11):2071-2083.
6. Han H.K., Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000, 2(1):E6.
7. Liederer B.M., Borchardt R.T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 2006, 95(6):1177-1195.
8. Yang J.Z., Chen W., Borchardt R.T. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J. Pharmacol. Exp. Ther. 2002, 303(2):840-848.
9. Meyer-Losic F., et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer Res. 2008, 14(7):2145-2153.
10. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 2009, 61(13):1177-1188.
11. Cheng J., et al. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem. 2003, 14(5):1007-1017.
12. Davis M.E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 2009, 61(13):1189-1192.
13. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 2008, 60(8):886-898.
14. DeFeo-Jones D., et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 2000, 6(11):1248-1252.
15. Kumaresan P.R., et al. Evaluation of ketone-oxime method for developing therapeutic on-demand cleavable immunoconjugates. Bioconjug. Chem. 2008, 19(6):1313-1318.
16. Cheng K., et al. Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J. Pharmacol. Exp. Ther. 2006, 317(2):797-805.
17. Lewis Phillips G.D., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68(22):9280-9290.
18. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 2009, 13(3):235-244.
19. Doronina S.O., et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug. Chem. 2008, 19(10):1960-1963.
20. Jaracz S., et al. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13(17):5043-5054.
21. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 2001, 53(2):171-216.
22. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5(2):147-159.
23. Stohrer M., et al. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60(15):4251-4255.
24. Adams G.P., et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998, 58(3):485-490.
25. Teicher B.A. Antibody-drug conjugate targets. Curr. Cancer Drug Targets 2009, 9(8):982-1004.
26. Gires O. Tumor-Associated Antigens: Identification, Characterization, and Clinical Applications 2009.
27. Wang W., et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol. Oncol. 2009, 27(5):525-528.
28. Spearman M.E., Goodwin R.M., Kau D. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. Drug Metab. Dispos. 1987, 15(5):640-647.
29. Quiles S., et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J. Med. Chem. 2010, 53(2):586-594.
30. Hamann P.R., et al. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug. Chem. 2005, 16(2):346-353.
31. Boghaert E.R., et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int. J. Oncol. 2008, 32(1):221-234.
32. Krop I.E., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010, 28(16):2698-2704.
33. Sievers E.L. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol. Dis. 2003, 31(1):7-10.
34. van Der Velden V.H., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001, 97(10):3197-3204.
35. Buckwalter M., et al. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J. Clin. Pharmacol. 2004, 44(8):873-880.
36. Mylotarg (gemtuzumab ozogamicin): Market Withdrawal cited; Available from:. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm.
37. Krop I., et al. A phase 2 study of trastuzumab-dm 1 (t-dm 1), a novel her 2 antibody-drug conjugate, in her 2+ metastatic breast cancer (mbc) patients previously treated with conventional chemotherapy, lapatinib and trastuzumab. San Antonio Brest Cancer Symposium 2009.
38. DiJoseph J.F., et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res. 2006, 12(1):242-249.
39. Tai W., Mahato R., Cheng K., et al. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 2010, 146(3):264-275.
40. Krop I.E., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010, 28(16):2698-2704.
41. Advani Anjali, E.G.*, Gisselbrecht Christian, Rohatiner Ama, Rosen Steven, Smith Mitchell, Boni* Joseph, Lejeune* Chantal, Patel Hemant Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). American Society of Hematology Annual Meeting 2005.
42. Khandare J.J., et al. Novel polymeric prodrug with multivalent components for cancer therapy. J. Pharmacol. Exp. Ther. 2006, 317(3):929-937.
43. Dharap S.S., et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl Acad. Sci. USA 2005, 102(36):12962-12967.
44. Chen X., et al. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 2005, 48(4):1098-1106.
45. Yoneda Y., et al. A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. Bioorg. Med. Chem. Lett. 2008, 18(5):1632-1636.
46. Shin B.K., et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 2003, 278(9):7607-7616.
47. Dubowchik G.M., Firestone R.A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8(23):3341-3346.
48. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 2005, 56:555-583.
49. Zhou J., et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37(9):3094-3109.
50. Sefah K., et al. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5(6):1169-1185.
51. Chu T.C., et al. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34(10):e73.
52. Farokhzad O.C., et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64(21):7668-7672.
53. Morris M.J., et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res. 2007, 13(9):2707-2713.
54. Milowsky M.I., et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 2007, 25(5):540-547.
55. Dhar S., et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 2008, 105(45):17356-17361.
56. Kolishetti N., et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(42):17939-17944.
57. Huang Y.F., et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10(5):862-868.
58. Shangguan D., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl Acad. Sci. USA 2006, 103(32):11838-11843.
59. Henne W.A., et al. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg. Med. Chem. Lett. 2006, 16(20):5350-5355.
60. Aronov O., et al. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem. 2003, 14(3):563-574.
61. V. Anbharasi, N. Cao, S.S. Feng, Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J. Biomed. Mater. Res. A. 94(3) 730-743.
62. Rubio-Aliaga I., et al. Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol. Cell. Biol. 2003, 23(9):3247-3252.
63. Kodama T. Antibodies that inhibit transport activity of peptide transporters 2010, US Patent 20100247539.
64. Landowski C.P., et al. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol. Cancer Ther. 2005, 4(4):659-667.
65. Nakanishi T., et al. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res. 1997, 57(18):4118-4122.
66. Nakanishi T., et al. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 2000, 88(2):274-280.
67. Gallop M.A. Gemcitabine Prodrugs, Pharmaceuticals Compositions and Uses Thereof 2010, 1-52. XenoPort, Inc., Santa Clare, CA (US): USA.
68. Stella V.J. Prodrugs: Challanges and Rewards, Part 1 2007.
69. Ramanathan S., et al. Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharm. Res. 2001, 18(7):950-956.
70. Minko T., et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 2002, 50(2):143-150.
71. Russell-Jones G., et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J. Inorg. Biochem. 2004, 98(10):1625-1633.
72. Yang W., et al. Targeting cancer cells with biotin-dendrimer conjugates. Eur. J. Med. Chem. 2009, 44(2):862-868.
73. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 1994, 83(4):601-606.
74. Eldon Michael A., C.-M.S., Viegas Tacey, Bentley Michael NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure. The 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007, C157.
75. Eldon Michael A., L.A., Staschen Carl-Michael, Viegas Tacey, Singhal Anil, M.R., Persson Heather, Bentley Michael Anti-tumor activity and pharmacokinetics of NKTR-102, a novel PEGylated-irinotecan conjugate, in irinotecan-resistant colorectal tumors implanted in mice. 14th European Cancer Conference 2007, P-0722.
76. Von Hoff D.D., G.S.J., Borad M.J., Rosen L.S., Utz4 J., Basche M., Alemany C., Dhar S., Acosta L., Barker T., Walling J., Hamm J.T. First Phase I Trial of NKTR-102 (PEG-irinotecan) Reveals Early Evidence of Broad Anti-Tumor Activity in Three Different Schedules in 2008 EORTC-NCI-AACR Symposium 2008, P-595.
77. Ronit Satchi-Fainaro R.D. Polymer therapeutics: polymers as drugs, conjugates and gene delivery systems. Advances in polymer science 2006, 36-37.
78. Sapra P., et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin. Cancer Res. 2008, 14(6):1888-1896.
79. Eldon Michael A., Neumann Theresa A., Wolff Ron, Cheng Lin, Viegas †Tacey X., Bentley †Michael D., Fishburn C.Simone, Kugler Alan R. NKTR-118 (oral PEG-Naloxol), a PEGylated derivative of Naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical models. The American Academy of Pain Management 18th Annual Clinical Meeting 2007, P-28.
80. Neumann Theresa A., Marcantonio Annette, Song Di, Morrison Paul J., Eldon Michael A., Kugler Alan R. Clinical investigation of NKTR-118 as a Selective oral peripheral opioid antagonist. The American Academy of Pain Management 18th Annual Clinical Meeting 2007, P-27.
81. Sabbatini P., et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2004, 22(22):4523-4531.
82. Vasey P.A., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5(1):83-94.
83. Seymour L.W., et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34(6):1629-1636.
84. Bhatt R., et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 2003, 46(1):190-193.
85. Lin N.U., et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest. New Drugs 2007, 25(4):369-375.
86. Homsi J., et al. Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 2007, 13(19):5855-5861.
87. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev. 2008, 60(8):899-914.
88. Oliver J.C., Y.Y., Synold T.W., Schluep T., Davis M. A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. 2008 ASCO Annual Meeting Proceedings 2008.
89. Stevens P.J., Sekido M., Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004, 21(12):2153-2157.
90. Lilja H., Abrahamsson P.A., Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J. Biol. Chem. 1989, 264(3):1894-1900.
91. Kumar S.K., et al. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg. Med. Chem. 2008, 16(6):2764-2768.
92. Mhaka A., et al. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg. Med. Chem. Lett. 2002, 12(17):2459-2461.
93. Kumar S.K., et al. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg. Med. Chem. 2007, 15(14):4973-4984.
94. Denmeade S.R., et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998, 58(12):2537-2540.
95. Denmeade S.R., et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl Cancer Inst. 2003, 95(13):990-1000.
96. Garsky V.M., et al. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J. Med. Chem. 2001, 44(24):4216-4224.
97. Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91(3):528-539.
98. Ross J.S., et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9(17):6357-6362.
99. Wright G.L., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48(2):326-334.
100. Mhaka A., et al. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther. 2004, 3(6):551-558.
101. Bagshawe K.D. Antibody-directed enzyme prodrug therapy (ADEPT). Adv. Pharmacol. 1993, 24:99-121.
102. Connor T.A. Prodrugs in cancer chemotherapy. Stem Cells 1995, 13(5):501-511.
103. Melton R.G., Sherwood R.F. Antibody-enzyme conjugates for cancer therapy. J. Natl Cancer Inst. 1996, 88(3-4):153-165.
104. Melton R.G. Antibody-directed enzyme prodrug therapy (ADEPT). Drugs Future 1996, 21:167.
105. Bagshawe K.D. Antibody-Directed Enzyme Prodrug Therapy 2007.
106. Alvarez R.D., et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 2002, 8(9):2806-2811.
107. Xiao J., et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother. Radiopharm. 2005, 20(1):16-26.
108. Fang L., et al. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J. Med. Chem. 2006, 49(21):6290-6297.
109. Francis R.J., et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 2002, 87(6):600-607.
110. Rigg A.S., Lemoine N.R. Genetic prodrug activation therapy for pancreatic cancer. Ann. NY Acad. Sci. 1999, 880:319-325.
111. Freeman S.M., et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993, 53(21):5274-5283.
112. Bi W.L., et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 1993, 4(6):725-731.
113. Huber B.E., et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl Acad. Sci. USA 1994, 91(17):8302-8306.
114. Pandha H.S., et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 1999, 17(7):2180-2189.
115. Ring C.J., et al. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 1996, 3(12):1094-1103.
116. Ring C.J., et al. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther. 1997, 4(10):1045-1052.
117. Hlavaty J., et al. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements. J. Virol. 2004, 78(3):1384-1392.
118. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 2008, 270(2):191-201.
119. Wu L., et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 2001, 8(18):1416-1426.
120. Chen C.S., Jounaidi Y., Waxman D.J. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab. Dispos. 2005, 33(9):1261-1267.
121. McCarthy H.O., et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003, 10(1):40-48.
122. Lu H., Chen C.S., Waxman D.J. Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009, 16(5):393-404.
123. Freytag S.O., et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 2007, 15(3):636-642.
124. Freytag S.O., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003, 63(21):7497-7506.
125. Klatzmann D., et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 1998, 9(17):2595-2604.
126. Fillat C., et al. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther. 2003, 3(1):13-26.
127. Chevez-Barrios P., et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J. Clin. Oncol. 2005, 23(31):7927-7935.
128. Kan O., Kingsman S., Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin. Biol. Ther. 2002, 2(8):857-868.
129. Braybrooke J.P., et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 2005, 11(4):1512-1520.
130. Searle P.F., et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 2004, 31(11):811-816.
131. Palmer D.H., et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 2004, 22(9):1546-1552.
132. Chung-Faye G., et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7(9):2662-2668.
133. Martin J., et al. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 1997, 40(3):189-201.
134. Napier M.P., et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 2000, 6(3):765-772.